Cardiovascular disease is the number one killer worldwide. Doctors fear a renewed epidemic of heart problems in 20 to 30 years time as a new generation of overweight and obese youngsters reaches middle age.
Researchers are concerned the hunt for new heart drugs is losing momentum as resources are switched to other areas. Given growing trends of obesity worldwide, everyone has reason to be concerned that the fight against heart disease could stall as a result.
The vast amounts required to be invested by pharmaceutical companies to obtain regulatory approval are tightening resources for new heart drugs and leading investors are shifting funding to areas, notably cancer research, where they can get a better bang for their buck.
Since the start of 2012, 17 new drugs been approved by the US Food and Drug Administration for cancer compared with just three for heart disease.
“There is a clear move of R&D from cardiovascular to cancer and other areas,” says Michel Komajda, a heart specialist and former president of the European Society of Cardiology (ESC).
Perhaps cardiology is a victim of the relative success of the global war on heart disease in reducing death rates, thanks to better drugs and prevention strategies such as anti-smoking campaigns. In Europe, the death rate from cardiovascular disease has halved over the past 30 years, while the risk of dying within 30 days of a heart attack has been cut by more than half in just 20 years.
However, with an ageing population, there are still big areas where we need progress, particularly in relation to preventing acute heart failure. Many patients remain at risk of clogged arteries, despite taking cholesterol-lowering statins, while heart failure - where the heart fails to pump blood adequately - remains a deadly disease that has seen little progress in treatment in 40 years.
Developing new heart drugs takes particularly heavy spending with uncertain returns. What is more, patent expiries mean many previously profitable heart drugs are now available as cheap generics, reducing drug companies’ revenue from the sector.
In contrast to oncology, where a better understanding of the genetics behind different tumours means drugs can be tested rapidly in small groups of highly targeted patients, heart drugs still need large and lengthy studies to prove a benefit.
These tests can each cost hundreds of millions of dollars, raising doubts as to whether cardiovascular research is money well spent - especially after recent high-profile setbacks. Both Pfizer and Roche for example have suffered disappointments with drugs designed to raise levels of “good” HDL cholesterol.
So far, however, working out how to target heart drugs effectively has proved elusive - a fact that has not been lost on investors in emerging medical technologies. A biotech company is more likely to choose oncology, because the path to approval is quicker, so even though there is a smaller patient population, investors are more likely to get a return than for more expensive and longer to prove cardiovascular drugs.
One research area that might deliver fresh impetus, doctors believe, is the emerging class of experimental cholesterol-lowering drugs known as PCSK9 inhibitors. These man-made antibodies are now in mid-stage studies. Given by injection, they offer a new way to fight atherosclerosis, (the build-up of artery-clogging fatty deposits,) but still need to prove themselves in late-stage tests.
Clearly there is more need for research on new heart drugs. However, with funding declining, we have reasons to worry the advances made over the past three decades will not be progressed as fast in coming years.
With a growing population worldwide at risk of developing heart disease, the slowdown of new heart drug research should be a higher concern to all.